Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 218

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role

Open access
Raal, Frederick J., Giugliano, Robert P., Sabatine, Marc S., Koren, Michael J., Blom, Dirk, Seidah, Nabil G., Honarpour, Narimon, Lira, Armando, Xue, Allen, Chiruvolu, Padmaja, Jackson, Simon, Di, Mei, Peach, Matthew, Somaratne, Ransi, Wasserman, Scott M., Scott, Rob, Stein, Evan A. · 2026 · Journal of Lipid Research

Abstract

Lipoprotein (a) [Lp(a)] is independently associated with CVD risk. Evolocumab, a monoclonal antibody (mAb) to proprotein convertase subtilisin/kexin type 9 (PCSK9), decreases Lp(a). The potential mechanisms were assessed. A pooled analysis of Lp(a) and LDL cholesterol (LDL-C) in 3,278 patients from 10 clinical trials (eight phase 2/3; two extensions) was conducted. Within each parent study, biweekly and monthly doses of evolocumab statistically significantly reduced Lp(a) at week 12 versus control (P < 0.001 within each study); pooled median (quartile 1, quartile 3) percent reductions were 24.7% (40.0, 3.6) and 21.7% (39.9, 4.2), respectively. Reductions were maintained through week 52 of the open-label extension, and correlated with LDL-C reductions [with and without correction for Lp(a)-cholesterol] at both time points (P < 0.0001). The effect of LDL and LDL receptor (LDLR) availability on Lp(a) cell-association was measured in HepG2 cells: cell-associated LDL fluorescence was reversed by unlabeled LDL and Lp(a). Lp(a) cell-association was reduced by coincubation with LDL and PCSK9 and reversed by adding PCSK9 mAb. These studies support that reductions in Lp(a) with PCSK9 inhibition are partly due to increased LDLR-mediated uptake. In most situations, Lp(a) appears to compete poorly with LDL for LDLR binding and internalization, but when LDLR expression is increased with evolocumab, particularly in the setting of low circulating LDL, Lp(a) is reduced.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jlr.2026.101063

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 218

Metadata

Authors
Raal, F. J., Giugliano, R. P., Sabatine, M. S., Koren, M. J., Blom, D., Seidah, N. G., Honarpour, N., Lira, A., Xue, A., Chiruvolu, P., Jackson, S., Di, M., Peach, M., Somaratne, R., Wasserman, S. M., Scott, R., & Stein, E. A.
Venue
Journal of Lipid Research
Publisher
Elsevier BV
Published
2026-06
Volume
67
Issue
6
Pages
101063
ISSN
0022-2275 (ISSN-L)
OpenAlex
W2415117000
Cited by
218
References
11
FWCI
33.85
Type
journal article
Language
en
Open access
gold
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role. https://app.cochat.ai/papers/10.1016/j.jlr.2026.101063
The paper
Raal, F. J., Giugliano, R. P., Sabatine, M. S., Koren, M. J., Blom, D., Seidah, N. G., Honarpour, N., Lira, A., Xue, A., Chiruvolu, P., Jackson, S., Di, M., Peach, M., Somaratne, R., Wasserman, S. M., Scott, R., & Stein, E. A. (2026). PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role. Journal of Lipid Research. https://doi.org/10.1016/j.jlr.2026.101063

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.